Arax Advisory Partners’s Q32 Bio QTTB Stock Holding History

Arax Advisory Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.37K	Buy	1,148 +37	+3%	+$176	﹤0.01%	2612
2025 Q4	$3.69K	Sell	1,111 -104	-9%	-$294	﹤0.01%	3009
2025 Q3	$2.4K	Buy	1,215 +104	+9%	+$200	﹤0.01%	3075
2025 Q2	$1.66K	Buy	+1,111	New	+$1.89K	﹤0.01%	2630

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arax Advisory Partners's QTTB Position: Q1 2026 in Review

Arax Advisory Partners increased its Q32 Bio (QTTB) stake by 3.3% in Q1 2026, buying an estimated $176 and bringing the position to 1,148 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2612.

Arax Advisory Partners first reported a position in QTTB in Q2 2025 and has held it in 4 quarters since. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

Arax Advisory Partners held 1,148 shares of Q32 Bio worth $7.37K as of Q1 2026.
Arax Advisory Partners bought 37 Q32 Bio shares in Q1 2026, an estimated $176.
Q32 Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2612 holding.
Arax Advisory Partners first reported a position in Q32 Bio in Q2 2025 and has held it in 4 quarters since.
54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.